Continuation of ceritinib beyond disease progression in ALK-positive NSCLC

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Enriqueta Felip, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses results from a retrospective study showing the continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Share this video